摘要
目的观察联合应用思力华(沙美特罗替卡松粉吸入剂)和舒利迭(噻托溴铵粉吸入剂)治疗稳定期慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)的临床疗效。方法96例稳定期中重度COPD患者被随机均分为两组,试验组(联合应用思力华和舒利迭)和对照组(仅应用舒利迭),两组患者治疗疗程为3个月。观察两组患者临床症状、动脉血气分析、肺功能的改善情况,比较两组患者治疗疗效的差异。结果①治疗后对照组和试验组患者临床症状均有明显改善,且试验组患者临床缓解率明显高于对照组患者,P<0.05,差异具有统计学意义。②治疗后对照组和试验组患者FEV1%、FEV1/FVC、PaO2均较治疗前升高,PaCO2较治疗前减低;且治疗后试验组患者较对照组患者FEV1%、FEV1/FVC、PaO2高,PaCO2较对照组低,P<0.05,差异具有统计学意义。③治疗组和对照组均无明显不良反应发生。结论联合应用思力华和舒利迭有利于改善COPD稳定期患者的肺功能。
Object ive To investigate the clinical efficacy of combination therapy with Salmeterol/Fluticasone and Tiotropium in stable COPD.Methods 96 patients with stable COPD were randomly divided into two groups：the test group （joint application） and the control group （only Tiotropium）,the treatment course for two groups is 3 months. Clinical symptoms,blood gas analysis and lung function were observed to compare the differences in treatment efficacy.Resu It ①clinical symptoms of the two groups showed significant improvement after treatment,and the clinical remission rate was significantly higher in test group with a statistical difference（P〈0.05）.②FEV1%,FEV1/FVC and PaO2 were higher but PaCO2 was lower in the two groups after treatment.After treatment,FEV1%,FEV1/ FVC and PaO2 in the test group were higher than the control group,and PaCO2 in the test group was lower than the control group.③No significant adverse reactions occurred in the two groups.Conclusion Combination therapy with Salmeterol/Fluticasone and Tiotropium can improve the lung function in stable COPD.
出处
《首都医药》
2013年第14期67-68,共2页
Capital Medicine
